Nutex Health (NASDAQ:NUTX) Upgraded by Wall Street Zen to “Strong-Buy” Rating

Nutex Health (NASDAQ:NUTX) was upgraded by research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Sunday.

Other research analysts also recently issued research reports about the company. B. Riley Financial started coverage on Nutex Health in a research note on Friday, June 26th. They set a “buy” rating and a $290.00 price target for the company. Weiss Ratings upgraded shares of Nutex Health from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, May 4th. Zacks Research upgraded shares of Nutex Health to a “hold” rating in a research report on Monday, June 29th. Finally, Lake Street Capital initiated coverage on shares of Nutex Health in a research report on Tuesday, June 2nd. They issued a “buy” rating and a $235.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Nutex Health currently has an average rating of “Moderate Buy” and a consensus target price of $243.33.

Nutex Health Price Performance

NASDAQ NUTX traded up $0.55 during mid-day trading on Friday, hitting $183.91. The stock had a trading volume of 86,559 shares, compared to its average volume of 122,222. The company has a 50 day simple moving average of $144.52 and a 200 day simple moving average of $131.07. The company has a market cap of $1.27 billion, a price-to-earnings ratio of 14.21 and a beta of 0.21. Nutex Health has a 52-week low of $77.21 and a 52-week high of $204.00. The company has a quick ratio of 3.12, a current ratio of 3.14 and a debt-to-equity ratio of 0.66.

Nutex Health (NASDAQ:NUTX) last posted its earnings results on Thursday, April 30th. The company reported $6.52 EPS for the quarter, topping analysts’ consensus estimates of $3.99 by $2.53. The company had revenue of $216.49 million for the quarter, compared to the consensus estimate of $227.80 million. Nutex Health had a return on equity of 23.50% and a net margin of 10.95%. Equities analysts forecast that Nutex Health will post 22.72 EPS for the current fiscal year.

Institutional Trading of Nutex Health

Hedge funds and other institutional investors have recently bought and sold shares of the company. Islay Capital Management LLC acquired a new position in Nutex Health in the 4th quarter valued at $34,000. BNP Paribas Financial Markets lifted its stake in shares of Nutex Health by 966.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 320 shares of the company’s stock worth $40,000 after purchasing an additional 290 shares during the period. Royal Bank of Canada boosted its holdings in shares of Nutex Health by 752.4% during the fourth quarter. Royal Bank of Canada now owns 358 shares of the company’s stock worth $59,000 after purchasing an additional 316 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Nutex Health by 6,590.3% during the fourth quarter. Bank of America Corp DE now owns 2,074 shares of the company’s stock worth $66,000 after purchasing an additional 2,043 shares during the last quarter. Finally, EverSource Wealth Advisors LLC purchased a new stake in shares of Nutex Health in the first quarter valued at $83,000. 5.32% of the stock is owned by hedge funds and other institutional investors.

About Nutex Health

Nutex Health, Inc (NASDAQ: NUTX) is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight?loss services and behavioral health support. By combining in?person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost?effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail?anchored centers, offering treatment for non?life?threatening injuries and illnesses, preventive screenings and basic primary care.